Mufg Securities Americas Inc. Invests $448,000 in DexCom, Inc. (NASDAQ:DXCM)

Mufg Securities Americas Inc. bought a new stake in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 5,767 shares of the medical device company’s stock, valued at approximately $448,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Private Trust Co. NA increased its position in DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares in the last quarter. Optiver Holding B.V. bought a new stake in DexCom in the 4th quarter valued at about $33,000. TD Private Client Wealth LLC increased its position in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC increased its position in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new stake in DexCom in the 4th quarter valued at about $38,000. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $85.67 on Friday. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $132.26. The stock’s 50 day moving average price is $71.70 and its 200-day moving average price is $77.51. The company has a market capitalization of $33.59 billion, a PE ratio of 59.91, a PEG ratio of 2.30 and a beta of 1.43. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the previous year, the company posted $0.32 EPS. DexCom’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 7,000 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now owns 135,482 shares of the company’s stock, valued at $10,002,636.06. The trade was a 4.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Jon Brown sold 13,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,926 shares of company stock worth $4,734,384. Insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Mizuho started coverage on DexCom in a report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price objective for the company. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Piper Sandler decreased their price objective on DexCom from $100.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, May 2nd. Finally, Barclays boosted their price objective on DexCom from $90.00 to $93.00 and gave the stock an “equal weight” rating in a report on Monday, May 5th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and an average target price of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.